What is Wezenla?
•
3 min read
According to the FDA, Wezlana (ustekinumab-auub) was approved on October 31, 2023, as the first interchangeable biosimilar to Stelara, meaning it is highly similar. In Europe, a similar ustekinumab biosimilar is authorized under the name Wezenla. This biologic medication, containing the active ingredient ustekinumab, treats inflammatory diseases by targeting specific proteins in the immune system.
